FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2271771390> ?p ?o ?g. }

• W2271771390 endingPage "65" @default.
• W2271771390 startingPage "854" @default.
• W2271771390 abstract "In patients with type 2 diabetes, intensive blood-glucose control with insulin or sulphonylurea therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks. This study investigated whether intensive glucose control with metformin has any specific advantage or disadvantage.Of 4075 patients recruited to UKPDS in 15 centres, 1704 overweight (>120% ideal bodyweight) patients with newly diagnosed type 2 diabetes, mean age 53 years, had raised fasting plasma glucose (FPG; 6.1-15.0 mmol/L) without hyperglycaemic symptoms after 3 months' initial diet. 753 were included in a randomised controlled trial, median duration 10.7 years, of conventional policy, primarily with diet alone (n=411) versus intensive blood-glucose control policy with metformin, aiming for FPG below 6 mmol/L (n=342). A secondary analysis compared the 342 patients allocated metformin with 951 overweight patients allocated intensive blood-glucose control with chlorpropamide (n=265), glibenclamide (n=277), or insulin (n=409). The primary outcome measures were aggregates of any diabetes-related clinical endpoint, diabetes-related death, and all-cause mortality. In a supplementary randomised controlled trial, 537 non-overweight and overweight patients, mean age 59 years, who were already on maximum sulphonylurea therapy but had raised FPG (6.1-15.0 mmol/L) were allocated continuing sulphonylurea therapy alone (n=269) or addition of metformin (n=268).Median glycated haemoglobin (HbA1c) was 7.4% in the metformin group compared with 8.0% in the conventional group. Patients allocated metformin, compared with the conventional group, had risk reductions of 32% (95% CI 13-47, p=0.002) for any diabetes-related endpoint, 42% for diabetes-related death (9-63, p=0.017), and 36% for all-cause mortality (9-55, p=0.011). Among patients allocated intensive blood-glucose control, metformin showed a greater effect than chlorpropamide, glibenclamide, or insulin for any diabetes-related endpoint (p=0.0034), all-cause mortality (p=0.021), and stroke (p=0.032). Early addition of metformin in sulphonylurea-treated patients was associated with an increased risk of diabetes-related death (96% increased risk [95% CI 2-275], p=0.039) compared with continued sulphonylurea alone. A combined analysis of the main and supplementary studies showed fewer metformin-allocated patients having diabetes-related endpoints (risk reduction 19% [2-33], p=0.033). Epidemiological assessment of the possible association of death from diabetes-related causes with the concurrent therapy of diabetes in 4416 patients did not show an increased risk in diabetes-related death in patients treated with a combination of sulphonylurea and metformin (risk reduction 5% [-33 to 32], p=0.78).Since intensive glucose control with metformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas, it may be the first-line pharmacological therapy of choice in these patients." @default.
• W2271771390 created "2016-06-24" @default.
• W2271771390 creator A5007719363 @default.
• W2271771390 creator A5009176775 @default.
• W2271771390 creator A5013587017 @default.
• W2271771390 creator A5017592396 @default.
• W2271771390 creator A5052221470 @default.
• W2271771390 creator A5071973947 @default.
• W2271771390 creator A5078571816 @default.
• W2271771390 creator A5083239533 @default.
• W2271771390 date "1998-09-12" @default.
• W2271771390 modified "2023-10-10" @default.
• W2271771390 title "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group." @default.
• W2271771390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9742977" @default.
• W2271771390 hasPublicationYear "1998" @default.
• W2271771390 type Work @default.
• W2271771390 sameAs 2271771390 @default.
• W2271771390 citedByCount "1834" @default.
• W2271771390 countsByYear W22717713902012 @default.
• W2271771390 countsByYear W22717713902013 @default.
• W2271771390 countsByYear W22717713902014 @default.
• W2271771390 countsByYear W22717713902015 @default.
• W2271771390 countsByYear W22717713902016 @default.
• W2271771390 countsByYear W22717713902017 @default.
• W2271771390 countsByYear W22717713902018 @default.
• W2271771390 countsByYear W22717713902019 @default.
• W2271771390 countsByYear W22717713902020 @default.
• W2271771390 countsByYear W22717713902021 @default.
• W2271771390 countsByYear W22717713902022 @default.
• W2271771390 countsByYear W22717713902023 @default.
• W2271771390 crossrefType "journal-article" @default.
• W2271771390 hasAuthorship W2271771390A5007719363 @default.
• W2271771390 hasAuthorship W2271771390A5009176775 @default.
• W2271771390 hasAuthorship W2271771390A5013587017 @default.
• W2271771390 hasAuthorship W2271771390A5017592396 @default.
• W2271771390 hasAuthorship W2271771390A5052221470 @default.
• W2271771390 hasAuthorship W2271771390A5071973947 @default.
• W2271771390 hasAuthorship W2271771390A5078571816 @default.
• W2271771390 hasAuthorship W2271771390A5083239533 @default.
• W2271771390 hasConcept C126322002 @default.
• W2271771390 hasConcept C134018914 @default.
• W2271771390 hasConcept C168563851 @default.
• W2271771390 hasConcept C203092338 @default.
• W2271771390 hasConcept C2777180221 @default.
• W2271771390 hasConcept C2779306644 @default.
• W2271771390 hasConcept C2780221984 @default.
• W2271771390 hasConcept C2780323712 @default.
• W2271771390 hasConcept C2780586474 @default.
• W2271771390 hasConcept C2780920962 @default.
• W2271771390 hasConcept C555293320 @default.
• W2271771390 hasConcept C71924100 @default.
• W2271771390 hasConceptScore W2271771390C126322002 @default.
• W2271771390 hasConceptScore W2271771390C134018914 @default.
• W2271771390 hasConceptScore W2271771390C168563851 @default.
• W2271771390 hasConceptScore W2271771390C203092338 @default.
• W2271771390 hasConceptScore W2271771390C2777180221 @default.
• W2271771390 hasConceptScore W2271771390C2779306644 @default.
• W2271771390 hasConceptScore W2271771390C2780221984 @default.
• W2271771390 hasConceptScore W2271771390C2780323712 @default.
• W2271771390 hasConceptScore W2271771390C2780586474 @default.
• W2271771390 hasConceptScore W2271771390C2780920962 @default.
• W2271771390 hasConceptScore W2271771390C555293320 @default.
• W2271771390 hasConceptScore W2271771390C71924100 @default.
• W2271771390 hasIssue "9131" @default.
• W2271771390 hasLocation W22717713901 @default.
• W2271771390 hasOpenAccess W2271771390 @default.
• W2271771390 hasPrimaryLocation W22717713901 @default.
• W2271771390 hasRelatedWork W1983641721 @default.
• W2271771390 hasRelatedWork W1996010611 @default.
• W2271771390 hasRelatedWork W2026226896 @default.
• W2271771390 hasRelatedWork W2033313326 @default.
• W2271771390 hasRelatedWork W2066345847 @default.
• W2271771390 hasRelatedWork W2072752555 @default.
• W2271771390 hasRelatedWork W2095179743 @default.
• W2271771390 hasRelatedWork W2141187912 @default.
• W2271771390 hasRelatedWork W2300682397 @default.
• W2271771390 hasRelatedWork W2744240433 @default.
• W2271771390 hasVolume "352" @default.
• W2271771390 isParatext "false" @default.
• W2271771390 isRetracted "false" @default.
• W2271771390 magId "2271771390" @default.
• W2271771390 workType "article" @default.